Most Popular News Stories on OBR Daily
The ten most read articles fromOBR Daily in the past month, updated continually:
(StreetInsider) Nov 17, 2017 - Increased compliance with Optune predicted survival in Novocure’s phase 3 pivotal EF-14 trial in newly diagnosed glioblastoma. An Optune compliance threshold as low as 50 percent correlated with significantly improved outcomes in patients treated with Optune together with temozolomide versus patients treated with temozolomide alone.
(Reuters) Nov 6, 2017 - Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer, and to market its drug Alecensa as a first choice of treatment for a subset of patients with non-small cell lung cancer.
(The Street) Nov 9, 2017 - The main ingredient in Monsanto's popular herbicide RoundUp has no firm link to cancer, according to a long-term study published in the Journal of the National Cancer Institute.
(MarketWatch) Oct 23, 2017 - Novartis AG said Monday that it received breakthrough therapy designation from the U.S. Food and Drug Administration for a skin cancer treatment that uses a combination of its Tafinlar and Mekinist drugs.
(WebMD/HealthDay News) Oct 24, 2017 - The high cost of cancer care in the United States has led more than one-quarter of patients to cut back on some part of their treatment, a new survey reveals.
(Reuters) Oct 29, 2017 - The proposed merger between U.S. pharmacy operator CVS Health Corp and No. 3 health insurer Aetna Inc represents a $66 billion bet that insurers can drive down high U.S. drug prices by cutting out the middleman.
(COA) Nov 1, 2017 - The Community Oncology Alliance (COA) applauds the Centers for Medicare & Medicaid Services (CMS) on its recent policy change to curb abuses of the 340B Drug Discount Program.
(StreetInsider) Oct 31, 2017 - Company plans to submit a single NDA requesting full approval of duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.
(BMS) Nov 10, 2017 - Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).
(MedPage Today) Nov 3, 2017 - A novel agent to prevent chemotherapy-induced neuropathy demonstrated evidence of efficacy in a phase IIb placebo-controlled clinical trial.